Αρχική World News Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC... World News Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations Από Ogkologos - 27 Ιανουαρίου, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma 23 Μαΐου, 2023 Diving into our role in 50 top cancer drugs 9 Φεβρουαρίου, 2022 EMA Recommends Granting a Marketing Authorisation for Poherdy 10 Απριλίου, 2026 POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... 17 Μαΐου, 2023 Φόρτωση περισσοτέρων HOT NEWS Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy... Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly... 120 years of Cancer Research UK: how science transformed survival rates